Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

Core Viewpoint - Aquestive Therapeutics, Inc. is actively participating in the Citizens Life Sciences Conference, indicating its commitment to engaging with investors and showcasing its innovative pharmaceutical developments [1][2]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines that significantly improve patients' lives through innovative science and delivery technologies [3]. - The company is developing orally administered and topical gel products aimed at delivering complex molecules, providing alternatives to traditional therapies [3]. - Currently, Aquestive has four commercialized products marketed by licensees in the U.S. and globally, and it serves as the exclusive manufacturer of these products [3]. - The company collaborates with other pharmaceutical firms to bring new molecules to market using proprietary technologies, such as PharmFilm® [3]. Product Development - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [3]. - An early-stage epinephrine prodrug topical gel product candidate is also in development for various dermatological conditions, including alopecia areata [3]. Upcoming Events - The management team will hold a fireside chat on May 8 at 10 am ET during the Citizens Life Sciences Conference, along with one-on-one meetings with investors [2]. - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [2].